PRINCETON, N.J., April 22, 2008 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. (Nasdaq:BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, will release first quarter 2008 financial results on Tuesday, April 29, 2008 at approximately 4:00 p.m. ET. The company will host a conference call that day at 4:30 p.m. ET to provide a company update and discuss the financial results for the quarter.
Conference call details:
Date: Tuesday, April 29, 2008
Time: 4:30 p.m. ET
Dial-in: 866-362-5158 (U.S.)
617-597-5397 (International)
Conference ID code: 84500511
Web cast: http://www.barriertherapeutics.com (Investor Relations
section)
An audio replay of the call will be available for thirty days:
Access: 888-286-8010 (U.S.)
617-801-6888 (International)
Replay Passcode: 20836996
About Barrier Therapeutics
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(r) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(r) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and superficial fungal infections. The company is headquartered in Princeton, New Jersey and has a wholly-owned subsidiary in Geel, Belgium. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.
Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics, Inc.